Significance of human papillomavirus 16/18 infection in association with p53 mutation in lung carcinomas

Clinical Respiratory Journal

Volumn 7, Issue 1, 2013, Pages 27-33

  Yu, Yan ^a   Yang, Aimin ^a   Hu, Senke ^a   Zhang, Jinghua ^a   Yan, Hong ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Human papilloma virus; Lung carcinoma; P53; Squamous cell carcinoma

Indexed keywords

PROTEIN P53;

ADULT; ARTICLE; CANCER STAGING; CHINA; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CARCINOMA; LUNG PARENCHYMA; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADULT; AGED; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, SQUAMOUS CELL; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; PROGNOSIS; RESPIRATORY TRACT NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84875640384     PISSN: 17526981     EISSN: 1752699X     Source Type: Journal    
DOI: 10.1111/j.1752-699X.2011.00277.x     Document Type: Article

References (31)

1. Syrjanen KJ, editor. Papillomavirus Infections in Human Pathology. New York, John Wiley & Sons, 2000: 201-5.
2. Munger K. The role of human papillomaviruses in human cancers. Front Biosci. 2002;7: 641-9.
3. 7 proteins. Clin Exp Immunol. 2010;159: 45-56.
4. Yanagawa N, Osakabe M, Hayashi M. Detection of HPV-DNA, p53 alterations, and methylation in penile squamous cell carcinoma in Japanese men. Pathol Int. 2008;58: 477-82.
5. Schiffman M, Castle PE, Jeronimo J, etal. Human papillomavirus and cervical cancer. Lancet 2007;370: 890-907.
6. World Health Organization. The World Health Organization histological typing of lung tumors. Am J Clin Pathol. 1982;77: 123-36.
7. Syrjanen KJ. Condylomatous changes in neoplastic bronchial epithelium. Report of a case. Respiration. 1979;38: 229-304.
8. Coissard CJ, Besson G, Polette MC, etal. Prevalence of human papillomaviruses in lung carcinomas: a study of 218 cases. Mod Pathol. 2005;18: 1606-9.
9. Ciotti M, Giuliani L, Ambrogi V, etal. Detection and expression of human papillomavirus oncogenes in non-small cell lung cancer. Oncol Rep. 2006;16: 183-9.
10. Buyru N, Altinisik J, Isin M, Dalay N. p53 codon 72 polymorphism and HPV status in lung cancer. Med Sci Monit. 2008;14: CR493-7.
11. Rezazadeh A, Laber DA, Ghim SJ, etal. The role of human papilloma virus in lung cancer: a review of the evidence. Am J Med Sci. 2009;338: 64-7.
12. 6 oncoprotein and survival in patients with stage I non-small cell lung cancer. Oncol Rep. 2009;21: 81-7.
13. Gillison ML, Shah KV. Role of mucosal human papillomavirus in non-genital cancers. J Natl Cancer Inst Monogr. 2003;31: 57-65.
14. Yu Y, Yang AM, Hu SK, Yan H. Correlation of HPV 16/18 infection of human papillomavirus with lung squamous cell carcinomas in Western China. Oncol Rep. 2009;21: 1627-32.
15. Boyer SN, Wazer DE, Band V. E7 protein of human papillomavirus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 1996;56: 4620-4.
16. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2: 342-50.
17. Munger K, Baldwin A, Edwards KM, etal. Mechanisms of human papillomavirus-induced oncogenesis. J Virol. 2004;78: 11451-60.
18. Psyrri A, Gouveris P, Vermorken JB. Human papillomavirus-related head and neck tumors: clinical and research implication. Curr Opin Oncol. 2009;21: 201-5.
19. Montenarh M. Biochemical properties of the growth suppressor/oncoprotein p53. Oncogene. 1992;7: 1673-80.
20. Bartkova J, Bartek J, Lukas J, etal. P53 protein alterations in human testicular cancer including pre-invasive intratubular germ-cell neoplasia. Int J Cancer. 1991;49: 196-202.
21. Midgley C, Fisher CJ, Bartek J, etal. Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. J Cell Sci. 1992;101: 183-9.
22. Drozenova J, Drazd'akova M, Povysil C, Duskova J. Cervical cancer precursors: cytohistologic correlation with the results of HPV testing. Cesk Patol. 2006;42: 20-3.
23. Syrjanen KJ, Syrjanen S. Papillomavirus Infection in Human Pathology. New York, John Wiley & Sons, 2000: 1-10: 355-78.
24. Tornesello ML, Losito S, Benincasa G, etal. Human papillomavirus (HPV) genotypes and HPV16 variants and risk of adenocarcinoma and squamous cell carcinoma of the cervix. Gynecol Oncol. 2011;121: 32-42.
25. Castellsagué X, Díaz M, de Sanjosé S, etal. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006;98: 303-15.
26. Vu HL, Sikora AG, Fu S, Kao J. HPV-induced oropharyngeal cancer, immune response and response to therapy. Cancer Lett. 2010;288: 149-55.
27. Fischer CA, Zlobec I, Green E, etal. Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality? Int J Cancer. 2010;126: 1256-62.
28. Wang Y, Wang A, Jiang R, etal. Human papillomavirus type 16 and 18 infection is associated with lung cancer patients from the central part of China. Oncol Rep. 2008;20: 333-9.
29. Iwakawa R, Kohno T, Enari M, etal. Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma. Cancer Sci. 2010;101: 1891-6.
30. Cheng YW, Wu MF, Wang J, etal. Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation. Cancer Res. 2007;67: 10686-93.
31. Pyeon D, Newton MA, Lambert PF, etal. Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus negative head/neck and cervical cancers. Cancer Res. 2007;67: 4605-19.